

Cardiac Marker Testing Market by Product (Reagent, Instrument), Component (Troponin I & T, CK-MB, Myoglobin, BNP, hs-CRP), Disease (Myocardial Infarction, Congestive Heart Failure, Atherosclerosis), Enduser (Lab, PoC, Academia) - Global Forecast to 2027

Market Report | 2022-10-12 | 205 pages | MarketsandMarkets

AVAILABLE LICENSES:

- Single User \$4950.00
- Multi User \$6650.00
- Corporate License \$8150.00
- Enterprise Site License \$10000.00

Report description:

The global cardiac marker testing market is projected to reach USD 7.7 Billion by 2027 from USD 5.0 Billion in 2022, at a CAGR of 8.7% during the forecast period. The growth in the cardiac marker testing market is majorly driven by the significant rising cases of cardiovascular diseases, rapid growth in older population, and increasing research & funding initiatives from public/private organizations to discover novel cardiac biomarkers with improved efficacy for diagnosing heart conditions. According to the American Heart Association (AHA), the prevalence of CVD in the US is projected to reach 40.5% of the total population by 2030, from 36.9% in 2010.

However, technical problems associated with sample collection and storage and issues related to regulatory and reimbursement systems are some of the factors expected to restrain market growth to a certain extent.

"Troponin I and T estimated held the largest share of cardiac marker testing market in 2021, by Biomarker Type "

Based on biomarker type, the cardiac marker testing market is segmented into Troponin I and T, Creatine Kinase-MB (CK-MB), Natriuretic Peptide (BNP and Nt-proBNP), Myoglobin, High-sensitivity C-reactive Protein (hs-CRP), and other cardiac biomarkers. The Troponin I and T segment accounted for the largest share of 51.1 % of the cardiac marker testing market in 2021. Factors such as high sensitivity and specificity, long elevation time (rises over 4-8 hours, peaks at 10-24 hours, and declines over ten days), and rapid prediction of outcomes are driving the growth of this segment. In addition, lab technicians are more familiar

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

with the use of these markers as compared to other biomarkers

"Laboratory testing facilities segment accounted for the largest share of the cardiac marker testing market in 2021, by End user ". Based on end users, the cardiac marker testing market is segmented into laboratory testing facilities, academic institutes, and point-of-care testing facilities. In 2021, the laboratory testing facilities segment accounted for the largest share of 61.4% of the global cardiac marker testing market. Factors such as high testing throughput, better sensitivity & diagnostic accuracy compared to POC testing, and high preference for laboratory testing over POCT testing are driving the growth of this segment.

"The Asia Pacific market to grow at the highest CAGR during the forecast period"

The cardiac marker testing market is segmented into five major regions, namely, North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Asia Pacific is estimated to be the fastest-growing market for cardiac marker testing during the forecast period. The Asia Pacific market is driven due rising growing investments by government agencies in emerging countries of Asia Pacific for the improvement of healthcare infrastructure, growing number of independent clinical laboratories, presence of large patient population, and strategies adopted by players to increase their cardiac testing product reach in Asia Pacific.

Breakdown of supply-side primary interviews:

- By Company Type: Tier 1: 48%, Tier 2: 36%, and Tier 3: 16%
- By Designation: C-level: 10%, D-level: 14%, and Others: 76%
- By Region: North America: 40%, Europe: 32%, APAC: 20%, Latin America: 5%, and the Middle East & Africa: 3%

The major players operating in the cardiac marker testing market are F.Hoffmann-La Roche AG (Switzerland), Abbott Laboratories (US), Danaher Corporation (US), Siemens Healthineers AG (Germany), PerkinElmer, Inc. (US), bioMerieux SA (France), Becton, Dickinson and Company (US), Bio-Rad Laboratories, Inc. (US), Thermo Fisher Scientific Inc. (US), DiaSorin (Italy), and Tosoh Corporation (Japan), LSI Medience Corporation (Japan), Quidel Corporation (US), Randox Laboratories (UK), Guangzhou Wondfo Biotech Co., Ltd. (China), Boditech Med Inc. (South Korea), Tulip Diagnostics (P) Ltd (India), BTNX Inc. (Canada), Response Biomedical (Canada), Alfa Scientific Designs, Inc. (US), CTK Biotech, Inc. (US), Creative Diagnostics (US), LifeSign LLC. (US), CardioGenics Holdings Inc (Canada), and Atlas Medical GmbH (Germany).

Research Coverage

This report studies the cardiac marker testing market based on the product, biomarker type, disease, end user, and region. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micromarkets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five major regions (and the respective countries in these regions).

Key Benefits of Buying the Report

This report focuses on various levels of analysis-industry trends, market share of top players, and company profiles, which together form basic views and analyze the competitive landscape, emerging segments of the cardiac marker testing market, and high-growth regions and their drivers, restraints, opportunities, and challenges. The report will help both established firms as well as new entrants/smaller firms to gauge the pulse of the market and garner greater market shares.

Table of Contents:

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

| | | |
|-----------|--|----|
| 1 | INTRODUCTION | 28 |
| 1.1 | STUDY OBJECTIVES | 28 |
| 1.2 | MARKET DEFINITION | 28 |
| 1.3 | STUDY SCOPE | 29 |
| 1.3.1 | MARKETS COVERED | 29 |
| 1.3.2 | GEOGRAPHIC SCOPE | 29 |
| 1.3.3 | INCLUSIONS & EXCLUSIONS | 30 |
| 1.3.4 | YEARS CONSIDERED | 30 |
| 1.4 | CURRENCY CONSIDERED | 30 |
| 1.5 | LIMITATIONS | 30 |
| 1.6 | MARKET STAKEHOLDERS | 31 |
| 1.7 | SUMMARY OF CHANGES | 31 |
| 2 | RESEARCH METHODOLOGY | 32 |
| 2.1 | RESEARCH DATA | 32 |
| FIGURE 1 | RESEARCH DESIGN | 32 |
| 2.1.1 | SECONDARY RESEARCH | 33 |
| 2.1.2 | PRIMARY RESEARCH | 34 |
| 2.1.2.1 | Key data from primary sources | 34 |
| FIGURE 2 | BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS | 35 |
| FIGURE 3 | CARDIAC MARKER TESTING MARKET: BREAKDOWN OF PRIMARIES | 35 |
| 2.2 | MARKET SIZE ESTIMATION | 35 |
| FIGURE 4 | RESEARCH METHODOLOGY: HYPOTHESIS BUILDING | 36 |
| 2.2.1 | REVENUE MAPPING-BASED MARKET ESTIMATION | 36 |
| 2.2.2 | MARKET ESTIMATION BASED ON END USERS | 37 |
| FIGURE 5 | CARDIAC MARKER TESTING MARKET: MARKET SIZE ESTIMATION | 37 |
| 2.2.3 | PRIMARY RESEARCH VALIDATION | 37 |
| 2.3 | DATA TRIANGULATION | 38 |
| FIGURE 6 | DATA TRIANGULATION METHODOLOGY | 38 |
| 2.4 | RESEARCH ASSUMPTIONS AND LIMITATIONS | 39 |
| 2.4.1 | RESEARCH ASSUMPTIONS | 39 |
| 2.4.2 | RESEARCH LIMITATIONS | 39 |
| 3 | EXECUTIVE SUMMARY | 40 |
| FIGURE 7 | CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2022 VS. 2027 (USD MILLION) | 40 |
| FIGURE 8 | CARDIAC MARKER TESTING MARKET, BY END USER, 2022 VS. 2027 (USD MILLION) | 41 |
| FIGURE 9 | GEOGRAPHICAL SNAPSHOT OF CARDIAC MARKER TESTING MARKET | 42 |
| 4 | PREMIUM INSIGHTS | 43 |
| 4.1 | CARDIAC MARKER TESTING MARKET OVERVIEW | 43 |
| FIGURE 10 | RIISING INCIDENCE OF CARDIOVASCULAR DISEASES AND ONGOING CLINICAL TRIALS FOR NOVEL BIOMARKERS TO DRIVE MARKET | 43 |
| 4.2 | CARDIAC MARKER TESTING MARKET SHARE, BY PRODUCT, 2022 VS. 2027 | 43 |
| FIGURE 11 | REAGENTS & KITS TO CONTINUE TO DOMINATE MARKET DURING FORECAST PERIOD | 43 |
| 4.3 | EUROPE: CARDIAC MARKER TESTING MARKET, BY END USER AND REGION | 44 |
| FIGURE 12 | LABORATORY TESTING FACILITIES SEGMENT ACCOUNTED FOR LARGEST SHARE IN 2021 | 44 |
| 4.4 | CARDIAC MARKER TESTING MARKET: GEOGRAPHICAL SNAPSHOT | 44 |

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

FIGURE 13 CHINA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD 44

5 MARKET OVERVIEW 45

5.1 INTRODUCTION 45

5.2 MARKET DYNAMICS 45

FIGURE 14 CARDIAC MARKER TESTING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 45

5.2.1 DRIVERS 46

5.2.1.1 Rising incidence of cardiovascular diseases 46

5.2.1.2 Increasing geriatric population and subsequent rise in heart conditions worldwide 46

5.2.1.3 Growing research & funding initiatives from public & private organizations 47

5.2.1.4 Rising clinical studies for identification of novel cardiac biomarkers 47

5.2.2 RESTRAINTS 47

5.2.2.1 Technical issues related to sample collection & storage 47

5.2.2.2 Unfavorable regulatory processes and limited reimbursement structure 48

5.2.3 OPPORTUNITIES 48

5.2.3.1 Point-of-care testing with cardiac biomarkers 48

5.2.3.2 Ongoing research on novel cardiac biomarkers for cardiovascular diseases 49

5.2.3.3 Emerging markets offer high-growth opportunities 49

5.2.4 CHALLENGES 50

5.2.4.1 Challenges associated with biomarker assay validation 50

5.3 REGULATORY SCENARIO 50

TABLE 1 KEY REGULATORY BODIES & GOVERNMENT AGENCIES 50

5.3.1 KEY REGULATORY GUIDELINES 51

5.3.1.1 US 51

TABLE 2 US: CLASSIFICATION OF IN VITRO DIAGNOSTIC DEVICES 51

FIGURE 15 US: REGULATORY PROCESS FOR IVD DEVICES 52

5.3.1.2 Canada 53

FIGURE 16 CANADA: REGULATORY PROCESS FOR IVD DEVICES IN CANADA 53

5.3.1.3 Europe 53

TABLE 3 EUROPE: CLASSIFICATION OF IVD DEVICES 53

FIGURE 17 EUROPE: REGULATORY PROCESS FOR IVD DEVICES 54

5.3.1.4 Japan 55

FIGURE 18 REGULATORY PROCESS FOR IVD DEVICES IN JAPAN 55

TABLE 4 JAPAN: CLASSIFICATION OF IVD REAGENTS CLASSIFICATION OF IVD REAGENTS IN JAPAN 55

TABLE 5 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 56

5.3.1.5 China 56

TABLE 6 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 56

5.3.1.6 India 56

FIGURE 19 INDIA: REGULATORY PROCESS FOR IVD DEVICES 57

5.3.1.7 Russia 57

TABLE 7 RUSSIA: CLASSIFICATION OF IVD DEVICES 57

5.3.1.8 Mexico 58

FIGURE 20 MEXICO: REGULATORY PROCESS FOR IVD DEVICES 58

TABLE 8 MEXICO: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 58

5.3.1.9 Brazil 59

FIGURE 21 BRAZIL: REGULATORY PROCESS FOR IVD DEVICES 59

5.3.1.10 South Korea 59

TABLE 9 SOUTH KOREA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 59

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

| | | |
|-----------|---|----|
| 5.4 | REIMBURSEMENT SCENARIO | 60 |
| TABLE 10 | REIMBURSEMENT CODES FOR VARIOUS BIOMARKERS | 60 |
| 5.5 | VALUE CHAIN ANALYSIS | 61 |
| FIGURE 22 | CARDIAC MARKER TESTING MARKET: VALUE CHAIN ANALYSIS | 61 |
| 5.6 | SUPPLY CHAIN ANALYSIS | 62 |
| FIGURE 23 | DIRECT DISTRIBUTION-PREFERRED STRATEGY FOR PROMINENT COMPANIES | 63 |
| 5.7 | ECOSYSTEM ANALYSIS: PARENT MARKET (IN VITRO DIAGNOSTICS) | 63 |
| 5.8 | PRICING ANALYSIS | 64 |
| 5.8.1 | AVERAGE SELLING PRICE OF CARDIAC MARKET TEST KITS BY KEY PLAYERS | 64 |
| TABLE 11 | CARDIAC BIOMARKER TROPONIN I AND T TEST KITS | 64 |
| TABLE 12 | CARDIAC BIOMARKER CK-MB TEST KITS | 64 |
| TABLE 13 | CARDIAC BIOMARKER BPN OR NT-PROBNP TEST KITS | 64 |
| TABLE 14 | CARDIAC BIOMARKER MYOGLOBIN TEST KITS | 64 |
| TABLE 15 | CARDIAC BIOMARKER C-REACTIVE PROTEIN (HS-CRP) TEST KITS | 65 |
| TABLE 16 | AVERAGE SELLING PRICE OF CARDIAC MARKET TEST KITS TREND, BY COUNTRY (USD) | 65 |
| 5.9 | PORTER'S FIVE FORCES ANALYSIS | 65 |
| TABLE 17 | CARDIAC MARKER TESTING MARKET: PORTER'S FIVE FORCES ANALYSIS | 65 |
| 5.9.1 | BARGAINING POWER OF BUYERS | 66 |
| 5.9.2 | BARGAINING POWER OF SUPPLIERS | 66 |
| 5.9.3 | THREAT OF NEW ENTRANTS | 66 |
| 5.9.4 | THREAT OF SUBSTITUTES | 66 |
| 5.9.5 | INTENSITY OF COMPETITIVE RIVALRY | 66 |
| 5.10 | PATENT ANALYSIS | 67 |
| FIGURE 24 | TOP 10 PATENT APPLICANTS FOR CARDIAC MARKER TESTING (JANUARY 2012-SEPTEMBER 2022) | 67 |
| FIGURE 25 | TOP 10 PATENT OWNERS FOR CARDIAC MARKER TESTING (JANUARY 2012-SEPTEMBER 2022) | 67 |
| 5.11 | KEY CONFERENCES & EVENTS (2022-2024) | 68 |
| TABLE 18 | CARDIAC MARKER TESTING MARKET: DETAILED LIST OF MAJOR CONFERENCES & EVENTS | 68 |
| 5.12 | CASE STUDY | 69 |
| 5.12.1 | DEVELOPMENT OF HIGH-SENSITIVITY TROPONIN I | 69 |
| TABLE 19 | CASE 1: DIAGNOSING LOWER LEVEL OF TROPONIN IN CARDIAC PATIENTS | 69 |
| 5.13 | TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES | 69 |
| 5.14 | KEY STAKEHOLDERS & BUYING CRITERIA | 70 |
| 5.14.1 | KEY STAKEHOLDERS | 70 |
| FIGURE 26 | INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS FOR CARDIAC MARKER TESTING KITS AND INSTRUMENTS | 70 |
| TABLE 20 | INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR PRODUCT SEGMENTS (%) | 70 |
| 5.15 | KEY BUYING CRITERIA BY END USERS | 71 |
| TABLE 21 | KEY BUYING CRITERIA FOR PRODUCTS | 71 |
| 6 | CARDIAC MARKER TESTING MARKET, BY PRODUCT | 72 |
| 6.1 | INTRODUCTION | 73 |
| TABLE 22 | CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020-2027 (USD MILLION) | 73 |
| 6.2 | REAGENTS & KITS | 73 |
| 6.2.1 | RISING VOLUME OF DIAGNOSTIC TESTS TO DRIVE DEMAND | 73 |
| TABLE 23 | CARDIAC MARKER TESTING MARKET FOR REAGENTS & KITS, BY REGION, 2020-2027 (USD MILLION) | 74 |
| TABLE 24 | CARDIAC MARKER TESTING MARKET FOR REAGENTS & KITS, BY BIOMARKER TYPE, 2020-2027 (USD MILLION) | 74 |
| 6.3 | INSTRUMENTS | 75 |
| TABLE 25 | CARDIAC MARKER TESTING MARKET FOR INSTRUMENTS, BY REGION, 2020-2027 (USD MILLION) | 75 |
| TABLE 26 | CARDIAC MARKER TESTING MARKET FOR INSTRUMENTS, BY TECHNOLOGY, 2020-2027 (USD MILLION) | 75 |

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

| | | |
|----------|---|----|
| TABLE 27 | CARDIAC MARKER TESTING MARKET FOR INSTRUMENTS, BY BIOMARKER TYPE, 2020-2027 (USD MILLION) | 76 |
| 6.3.1 | CHEMILUMINESCENCE | 76 |
| 6.3.1.1 | Most preferred method for quantification of cardiac biomarkers to drive segment growth | 76 |
| TABLE 28 | CARDIAC MARKER TESTING MARKET FOR CHEMILUMINESCENCE, BY REGION, 2020-2027 (USD MILLION) | 77 |
| TABLE 29 | CARDIAC MARKER TESTING MARKET FOR CHEMILUMINESCENCE, BY BIOMARKER TYPE, 2020-2027 (USD MILLION) | 77 |
| 6.3.2 | IMMUNOFLUORESCENCE | 78 |
| 6.3.2.1 | Demand for stable and safer reagents to support market growth | 78 |
| TABLE 30 | CARDIAC MARKER TESTING MARKET FOR IMMUNOFLUORESCENCE, BY REGION, 2020-2027 (USD MILLION) | 78 |
| TABLE 31 | CARDIAC MARKER TESTING MARKET FOR IMMUNOFLUORESCENCE, BY BIOMARKER TYPE, 2020-2027 (USD MILLION) | 79 |
| 6.3.3 | ELISA | 79 |
| 6.3.3.1 | Long shelf life and ease of use to propel segment growth | 79 |
| TABLE 32 | CARDIAC MARKER TESTING MARKET FOR ELISA, BY REGION, 2020-2027 (USD MILLION) | 79 |
| TABLE 33 | CARDIAC MARKER TESTING MARKET FOR ELISA, BY BIOMARKER TYPE, 2020-2027 (USD MILLION) | 80 |
| 6.3.4 | IMMUNOCHROMATOGRAPHY | 80 |
| 6.3.4.1 | Increasing use in point-of-care settings to drive adoption of this technique | 80 |
| TABLE 34 | CARDIAC MARKER TESTING MARKET FOR IMMUNOCHROMATOGRAPHY, BY REGION, 2020-2027 (USD MILLION) | 81 |
| TABLE 35 | CARDIAC MARKER TESTING MARKET FOR IMMUNOCHROMATOGRAPHY, BY BIOMARKER TYPE, 2020-2027 (USD MILLION) | 81 |
| 7 | CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE | 82 |
| 7.1 | INTRODUCTION | 83 |
| TABLE 36 | CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2020-2027 (USD MILLION) | 83 |
| 7.2 | TROPONIN I AND T | 83 |
| 7.2.1 | HIGH SENSITIVITY AND SPECIFICITY IN DETECTION OF CVD TO DRIVE MARKET | 83 |
| TABLE 37 | CHARACTERISTICS OF TROPONIN CARDIAC MARKERS | 84 |
| TABLE 38 | CARDIAC MARKER TESTING MARKET FOR TROPONIN I AND T, BY REGION, 2020-2027 (USD MILLION) | 84 |
| TABLE 39 | CARDIAC MARKER TESTING MARKET FOR TROPONIN I AND T, BY DISEASE, 2020-2027 (USD MILLION) | 85 |
| TABLE 40 | CARDIAC MARKER TESTING MARKET FOR TROPONIN I AND T, BY END USER, 2020-2027 (USD MILLION) | 85 |
| 7.3 | CREATINE KINASE-MB (CK-MB) | 85 |
| 7.3.1 | DIAGNOSIS OF ACUTE MYOCARDIAL INJURY USING CK-MB TO DRIVE MARKET | 85 |
| TABLE 41 | CHARACTERISTICS OF CK-MB CARDIAC MARKER | 86 |
| TABLE 42 | CARDIAC MARKER TESTING MARKET FOR CREATINE KINASE-MB (CK-MB), BY REGION, 2020-2027 (USD MILLION) | 86 |
| TABLE 43 | CARDIAC MARKER TESTING MARKET FOR CREATINE KINASE-MB (CK-MB), BY DISEASE, 2020-2027 (USD MILLION) | 87 |
| TABLE 44 | CARDIAC MARKER TESTING MARKET FOR CREATINE KINASE-MB (CK-MB), BY END USER, 2020-2027 (USD MILLION) | 87 |
| ? | | |
| 7.4 | NATRIURETIC PEPTIDE (BNP AND NT-PROBNP) | 87 |
| 7.4.1 | USE OF BNP WITH OTHER CARDIAC MARKERS TO ENHANCE UTILIZATION | 87 |
| TABLE 45 | CARDIAC MARKER TESTING MARKET FOR NATRIURETIC PEPTIDE (BNP AND NT-PROBNP), BY REGION, 2020-2027 (USD MILLION) | 88 |
| TABLE 46 | CARDIAC MARKER TESTING MARKET FOR NATRIURETIC PEPTIDE (BNP AND NT-PROBNP), BY DISEASE, 2020-2027 (USD MILLION) | 88 |
| TABLE 47 | CARDIAC MARKER TESTING MARKET FOR NATRIURETIC PEPTIDE (BNP AND NT-PROBNP), BY END USER, 2020-2027 (USD MILLION) | 89 |
| 7.5 | MYOGLOBIN | 89 |
| 7.5.1 | RAPID INCREASE AND NORMALIZATION ASSOCIATED WITH MYOGLOBIN TO DRIVE MARKET | 89 |
| TABLE 48 | CHARACTERISTICS OF MYOGLOBIN CARDIAC MARKERS | 89 |
| TABLE 49 | CARDIAC MARKER TESTING MARKET FOR MYOGLOBIN, BY REGION, 2020-2027 (USD MILLION) | 90 |
| TABLE 50 | CARDIAC MARKER TESTING MARKET FOR MYOGLOBIN, BY DISEASE, 2020-2027 (USD MILLION) | 90 |

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 51 □CARDIAC MARKER TESTING MARKET FOR MYOGLOBIN, BY END USER, 2020-2027 (USD MILLION) □91

7.6 □HIGH-SENSITIVITY C-REACTIVE PROTEIN (HSCR) □91

7.6.1 □ABILITY OF HSCR TESTS TO ACCURATELY MEASURE LOW LEVELS OF CRP TO SUPPORT MARKET GROWTH □91

TABLE 52 □CUT-OFFS FOR CRP USING STANDARDIZED ASSAYS □91

TABLE 53 □CARDIAC MARKER TESTING MARKET FOR HIGH-SENSITIVITY C-REACTIVE PROTEIN (HSCR), BY REGION, 2020-2027 (USD MILLION) □92

TABLE 54 □CARDIAC MARKER TESTING MARKET FOR HIGH-SENSITIVITY C-REACTIVE PROTEIN (HSCR), BY DISEASE, 2020-2027 (USD MILLION) □92

TABLE 55 □CARDIAC MARKER TESTING MARKET FOR HIGH-SENSITIVITY C-REACTIVE PROTEIN (HSCR), BY END USER, 2020-2027 (USD MILLION) □93

7.7 □OTHER CARDIAC BIOMARKERS □93

TABLE 56 □CARDIAC MARKER TESTING MARKET FOR OTHER CARDIAC BIOMARKERS, BY REGION, 2020-2027 (USD MILLION) □94

TABLE 57 □CARDIAC MARKER TESTING MARKET FOR OTHER CARDIAC BIOMARKERS, BY DISEASE, 2020-2027 (USD MILLION) □94

TABLE 58 □CARDIAC MARKER TESTING MARKET FOR OTHER CARDIAC BIOMARKERS, BY END USER, 2020-2027 (USD MILLION) □95

8 □CARDIAC MARKER TESTING MARKET, BY DISEASE □96

8.1 □INTRODUCTION □97

TABLE 59 □CARDIAC MARKER TESTING MARKET, BY DISEASE, 2020-2027 (USD MILLION) □97

8.2 □MYOCARDIAL INFARCTION □97

8.2.1 □AVAILABILITY OF HIGH-SENSITIVITY BIOMARKERS FOR DETECTION OF MI TO DRIVE MARKET □97

TABLE 60 □CARDIAC MARKER TESTING MARKET FOR MYOCARDIAL INFARCTION, BY REGION, 2020-2027 (USD MILLION) □98

?

8.3 □CONGESTIVE HEART FAILURE □98

8.3.1 □INCREASING USE OF MULTI-MARKER TESTING TO SUPPORT MARKET GROWTH □98

TABLE 61 □CARDIAC MARKER TESTING MARKET FOR CONGESTIVE HEART FAILURE, BY REGION, 2020-2027 (USD MILLION) □99

8.4 □ACUTE CORONARY SYNDROME □99

8.4.1 □INCREASING INCIDENCE OF RISK FACTORS ASSOCIATED WITH ACS TO DRIVE ADOPTION OF CARDIAC MARKERS □99

TABLE 62 □CARDIAC MARKER TESTING MARKET FOR ACUTE CORONARY SYNDROME, BY REGION, 2020-2027 (USD MILLION) □100

8.5 □ATHEROSCLEROSIS □100

8.5.1 □HIGH PREVALENCE OF ATHEROSCLEROSIS TO DRIVE UPTAKE OF CARDIAC MARKERS □100

TABLE 63 □CARDIAC MARKER TESTING MARKET FOR ATHEROSCLEROSIS, BY REGION, 2020-2027 (USD MILLION) □101

8.6 □ISCHEMIA □101

8.6.1 □MULTIPLE COMPLICATIONS CAUSED BY ISCHEMIA TO DRIVE ADOPTION OF DIAGNOSTIC TESTS □101

TABLE 64 □CARDIAC MARKER TESTING MARKET FOR ISCHEMIA, BY REGION, 2020-2027 (USD MILLION) □101

9 □CARDIAC MARKER TESTING MARKET, BY END USER □102

9.1 □INTRODUCTION □103

TABLE 65 □CARDIAC MARKER TESTING MARKET, BY END USER, 2020-2027 (USD MILLION) □103

9.2 □LABORATORY TESTING FACILITIES □103

TABLE 66 □CARDIAC MARKER TESTING MARKET FOR LABORATORY TESTING FACILITIES, BY TYPE, 2020-2027 (USD MILLION) □104

TABLE 67 □CARDIAC MARKER TESTING MARKET FOR LABORATORY TESTING FACILITIES, BY REGION, 2020-2027 (USD MILLION) □104

9.2.1 □HOSPITAL LABORATORIES □104

9.2.1.1 □Emergency patient care and early diagnosis associated with in-house labs to drive market □104

TABLE 68 □CARDIAC MARKER TESTING MARKET FOR HOSPITAL LABORATORIES, BY REGION, 2020-2027 (USD MILLION) □105

9.2.2 □REFERENCE LABORATORIES □105

9.2.2.1 □Affordable and time-efficient services associated with reference laboratories to support market growth □105

TABLE 69 □CARDIAC MARKER TESTING MARKET FOR REFERENCE LABORATORIES, BY REGION, 2020-2027 (USD MILLION) □105

9.2.3 □CONTRACT TESTING LABORATORIES □106

9.2.3.1 □Ability to perform multiple tests and cover wider matrices to support market growth □106

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 70 □ CARDIAC MARKER TESTING MARKET FOR CONTRACT TESTING LABORATORIES, BY REGION, 2020-2027 (USD MILLION) □ 106
?
9.3 □ ACADEMIC INSTITUTES □ 106
9.3.1 □ CONTINUOUS RESEARCH & DEVELOPMENT OF NOVEL BIOMARKERS TO DRIVE MARKET □ 106
TABLE 71 □ CARDIAC MARKER TESTING MARKET FOR ACADEMIC INSTITUTES, BY REGION, 2020-2027 (USD MILLION) □ 107
9.4 □ POINT-OF-CARE TESTING FACILITIES □ 107
9.4.1 □ EARLY DETECTION AND LOWER TURNAROUND TIME TO DRIVE MARKET □ 107
TABLE 72 □ CARDIAC MARKER TESTING MARKET FOR POINT-OF-CARE TESTING FACILITIES, BY REGION, 2020-2027 (USD MILLION) □ 108
10 □ CARDIAC MARKER TESTING MARKET, BY REGION □ 109
10.1 □ INTRODUCTION □ 110
TABLE 73 □ CARDIAC MARKER TESTING MARKET, BY REGION, 2020-2027 (USD MILLION) □ 110
10.2 □ NORTH AMERICA □ 110
FIGURE 27 □ NORTH AMERICA: CARDIAC MARKER TESTING MARKET SNAPSHOT □ 111
TABLE 74 □ NORTH AMERICA: CARDIAC MARKER TESTING MARKET, BY COUNTRY, 2020-2027 (USD MILLION) □ 111
TABLE 75 □ NORTH AMERICA: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2020-2027 (USD MILLION) □ 112
TABLE 76 □ NORTH AMERICA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020-2027 (USD MILLION) □ 112
TABLE 77 □ NORTH AMERICA: CARDIAC MARKER TESTING INSTRUMENTS, BY TECHNOLOGY, 2020-2027 (USD MILLION) □ 113
TABLE 78 □ NORTH AMERICA: CARDIAC MARKER TESTING MARKET, BY END USER, 2020-2027 (USD MILLION) □ 113
10.2.1 □ US □ 113
10.2.1.1 □ Growing support from NIH for development of novel cardiac biomarkers to drive market □ 113
TABLE 79 □ US: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020-2027 (USD MILLION) □ 114
10.2.2 □ CANADA □ 114
10.2.2.1 □ Increasing government initiatives supporting cardiac marker testing to boost market growth □ 114
TABLE 80 □ CANADA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020-2027 (USD MILLION) □ 115
10.3 □ EUROPE □ 115
TABLE 81 □ EUROPE: CARDIAC MARKER TESTING MARKET, BY COUNTRY, 2020-2027 (USD MILLION) □ 115
TABLE 82 □ EUROPE CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2020-2027 (USD MILLION) □ 116
TABLE 83 □ EUROPE: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020-2027 (USD MILLION) □ 116
TABLE 84 □ EUROPE: CARDIAC MARKER TESTING MARKET FOR INSTRUMENTS, BY TECHNOLOGY, 2020-2027 (USD MILLION) □ 116
TABLE 85 □ EUROPE: CARDIAC MARKER TESTING MARKET, BY END USER, 2020-2027 (USD MILLION) □ 117
10.3.1 □ GERMANY □ 117
10.3.1.1 □ Higher healthcare expenditure to drive demand for diagnostic tests □ 117
TABLE 86 □ GERMANY: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020-2027 (USD MILLION) □ 117
10.3.2 □ UK □ 118
10.3.2.1 □ Government initiatives to expand diagnostic facilities to boost adoption of cardiac biomarkers □ 118
TABLE 87 □ UK: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020-2027 (USD MILLION) □ 118
10.3.3 □ FRANCE □ 118
10.3.3.1 □ Rising demand for early CVD diagnosis to drive market □ 118
TABLE 88 □ FRANCE: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020-2027 (USD MILLION) □ 119
10.3.4 □ ITALY □ 119
10.3.4.1 □ Adoption of advanced diagnostic technologies to drive market □ 119
TABLE 89 □ ITALY: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020-2027 (USD MILLION) □ 119
10.3.5 □ SPAIN □ 120
10.3.5.1 □ Establishment of large and advanced laboratories to drive uptake of cardiac marker testing □ 120
TABLE 90 □ SPAIN: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020-2027 (USD MILLION) □ 120

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

10.3.6 REST OF EUROPE (ROE) 120

TABLE 91 REST OF EUROPE: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020-2027 (USD MILLION) 121

10.4 ASIA PACIFIC 121

FIGURE 28 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET SNAPSHOT 122

TABLE 92 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET, BY COUNTRY, 2020-2027 (USD MILLION) 123

TABLE 93 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2020-2027 (USD MILLION) 123

TABLE 94 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020-2027 (USD MILLION) 124

TABLE 95 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET FOR INSTRUMENTS, BY TECHNOLOGY, 2020-2027 (USD MILLION) 124

TABLE 96 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET, BY END USER, 2020-2027 (USD MILLION) 124

10.4.1 JAPAN 125

10.4.1.1 Presence of established healthcare system with advanced laboratory facilities to drive market 125

TABLE 97 JAPAN: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020-2027 (USD MILLION) 125

10.4.2 CHINA 125

10.4.2.1 Increasing number of independent clinical laboratories to drive demand for cardiac markers 125

TABLE 98 CHINA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020-2027 (USD MILLION) 126

10.4.3 INDIA 126

10.4.3.1 Presence of large patient population to drive demand for cardiac marker testing 126

TABLE 99 INDIA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020-2027 (USD MILLION) 127

10.4.4 SOUTH KOREA 127

10.4.4.1 Growing number of private hospitals to drive adoption of advanced testing services 127

TABLE 100 SOUTH KOREA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020-2027 (USD MILLION) 127

10.4.5 AUSTRALIA 128

10.4.5.1 High healthcare expenditure to support market growth 128

TABLE 101 AUSTRALIA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020-2027 (USD MILLION) 128

10.4.6 REST OF ASIA PACIFIC (ROAPAC) 128

TABLE 102 REST OF ASIA PACIFIC: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020-2027 (USD MILLION) 128

10.5 LATIN AMERICA 129

TABLE 103 LATIN AMERICA: CARDIAC MARKER TESTING MARKET, BY COUNTRY, 2020-2027 (USD MILLION) 129

TABLE 104 LATIN AMERICA: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2020-2027 (USD MILLION) 130

TABLE 105 LATIN AMERICA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020-2027 (USD MILLION) 130

TABLE 106 LATIN AMERICA: CARDIAC MARKER TESTING MARKET FOR INSTRUMENTS, BY TECHNOLOGY, 2020-2027 (USD MILLION) 130

TABLE 107 LATIN AMERICA: CARDIAC MARKER TESTING MARKET, BY END USER, 2020-2027 (USD MILLION) 131

10.5.1 BRAZIL 131

10.5.1.1 Rising government support for advancements in healthcare to support market growth 131

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

| | | |
|-----------|---|-----|
| TABLE 108 | BRAZIL: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020-2027 (USD MILLION) | 131 |
| 10.5.2 | MEXICO | 132 |
| 10.5.2.1 | Rising demand for technologically advanced products to drive uptake for cardiac markers | 132 |
| TABLE 109 | MEXICO: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020-2027 (USD MILLION) | 132 |
| 10.5.3 | REST OF LATIN AMERICA (ROLATAM) | 132 |
| TABLE 110 | REST OF LATIN AMERICA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020-2027 (USD MILLION) | 133 |
| 10.6 | MIDDLE EAST & AFRICA | 133 |
| 10.6.1 | RISING IMPROVEMENTS IN HEALTHCARE INFRASTRUCTURE TO DRIVE DEMAND FOR ADVANCED MARKERS | 133 |
| TABLE 111 | MIDDLE EAST & AFRICA: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2020-2027 (USD MILLION) | 133 |
| TABLE 112 | MIDDLE EAST & AFRICA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020-2027 (USD MILLION) | 134 |
| TABLE 113 | MIDDLE EAST & AFRICA: CARDIAC MARKER TESTING MARKET FOR INSTRUMENTS, BY TECHNOLOGY, 2020-2027 (USD MILLION) | 134 |
| TABLE 114 | MIDDLE EAST & AFRICA: CARDIAC MARKER TESTING MARKET, BY END USER, 2020-2027 (USD MILLION) | 134 |
| 11 | COMPETITIVE LANDSCAPE | 135 |
| 11.1 | OVERVIEW | 135 |
| 11.2 | STRATEGIES ADOPTED BY KEY PLAYERS/RIGHT TO WIN | 135 |
| FIGURE 29 | OVERVIEW OF STRATEGIES ADOPTED BY COMPANIES (2019?2022) | 136 |
| 11.3 | REVENUE ANALYSIS | 137 |
| FIGURE 30 | REVENUE SHARE ANALYSIS OF TOP FIVE PLAYERS (2018?2021) | 137 |
| 11.4 | CARDIAC MARKER TESTING MARKET: MARKET SHARE ANALYSIS, BY KEY PLAYER (2021) | 137 |
| FIGURE 31 | CARDIAC MARKER TESTING MARKET SHARE, BY KEY PLAYER (2021) | 138 |
| TABLE 115 | CARDIAC MARKER TESTING MARKET: DEGREE OF COMPETITION | 138 |
| 11.5 | COMPANY EVALUATION QUADRANT FOR MAJOR PLAYERS (AS OF 2021) | 139 |
| 11.5.1 | STARS | 139 |
| 11.5.2 | EMERGING LEADERS | 139 |
| 11.5.3 | PERVASIVE PLAYERS | 139 |
| 11.5.4 | PARTICIPANTS | 140 |
| FIGURE 32 | CARDIAC MARKER TESTING MARKET: COMPANY EVALUATION QUADRANT (2021) | 140 |
| 11.6 | COMPANY EVALUATION QUADRANT (SMES/STARTUPS) | 141 |
| 11.6.1 | PROGRESSIVE COMPANIES | 141 |
| 11.6.2 | RESPONSIVE COMPANIES | 141 |
| 11.6.3 | DYNAMIC COMPANIES | 141 |
| 11.6.4 | STARTING BLOCKS | 141 |
| FIGURE 33 | CARDIAC MARKER TESTING MARKET: COMPETITIVE LEADERSHIP MAPPING (SMES/STARTUPS) | 142 |
| 11.7 | COMPETITIVE BENCHMARKING | 143 |
| TABLE 116 | OVERALL FOOTPRINT ANALYSIS | 143 |
| TABLE 117 | PRODUCT FOOTPRINT ANALYSIS | 144 |
| TABLE 118 | REGIONAL FOOTPRINT ANALYSIS | 145 |
| 11.8 | COMPETITIVE SCENARIO (2019-2022) | 146 |
| 11.8.1 | PRODUCT LAUNCHES & APPROVALS | 146 |
| 11.8.2 | DEALS | 147 |
| 11.8.3 | OTHER DEVELOPMENTS | 147 |
| ? | | |

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

12 COMPANY PROFILES 148

(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*

12.1 KEY PLAYERS 148

12.1.1 F. HOFFMANN-LA ROCHE AG 148

TABLE 119 F. HOFFMANN-LA ROCHE AG: BUSINESS OVERVIEW 148

FIGURE 34 F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT (2021) 149

12.1.2 ABBOTT LABORATORIES 152

TABLE 120 ABBOTT LABORATORIES: BUSINESS OVERVIEW 152

FIGURE 35 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2021) 153

12.1.3 SIEMENS HEALTHINEERS AG 156

TABLE 121 SIEMENS HEALTHINEERS AG: BUSINESS OVERVIEW 156

FIGURE 36 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2021) 157

12.1.4 DANAHER CORPORATION 160

TABLE 122 DANAHER CORPORATION: BUSINESS OVERVIEW 160

FIGURE 37 DANAHER CORPORATION: COMPANY SNAPSHOT (2021) 161

12.1.5 BIOMERIEUX SA 163

TABLE 123 BIOMERIEUX SA: BUSINESS OVERVIEW 163

FIGURE 38 BIOMERIEUX SA: COMPANY SNAPSHOT (2021) 164

12.1.6 BECTON, DICKINSON AND COMPANY (BD) 165

TABLE 124 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW 165

FIGURE 39 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2021) 166

12.1.7 BIO-RAD LABORATORIES, INC. 168

TABLE 125 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW 168

FIGURE 40 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2021) 169

12.1.8 THERMO FISHER SCIENTIFIC INC. 171

TABLE 126 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW 171

FIGURE 41 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2021) 172

12.1.9 DIASORIN 174

TABLE 127 DIASORIN: BUSINESS OVERVIEW 174

FIGURE 42 DIASORIN: COMPANY SNAPSHOT (2021) 175

12.1.10 PERKINELMER, INC. 177

TABLE 128 PERKINELMER INC: BUSINESS OVERVIEW 177

FIGURE 43 PERKINELMER INC: COMPANY SNAPSHOT (2021) 178

12.1.11 TOSOH CORPORATION 180

TABLE 129 TOSOH CORPORATION: BUSINESS OVERVIEW 180

FIGURE 44 TOSOH CORPORATION: COMPANY SNAPSHOT (2022) 181

12.1.12 LSI MEDIENCE CORPORATION (PHC HOLDINGS CORPORATION) 184

TABLE 130 LSI MEDIENCE CORPORATION: BUSINESS OVERVIEW 184

FIGURE 45 PHC HOLDINGS CORPORATION: COMPANY SNAPSHOT (2021) 184

12.1.13 QUIDEL CORPORATION 186

TABLE 131 QUIDEL CORPORATION: BUSINESS OVERVIEW 186

FIGURE 46 QUIDEL CORPORATION: COMPANY SNAPSHOT (2021) 186

12.1.14 RANDOX LABORATORIES 188

TABLE 132 RANDOX LABORATORIES: BUSINESS OVERVIEW 188

12.1.15 GUANGZHOU WONDFO BIOTECH CO., LTD. 190

TABLE 133 GUANGZHOU WONDFO BIOTECH CO., LTD.: BUSINESS OVERVIEW 190

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 12.1.16 BODITECH MED INC. 192
- TABLE 134 BODITECH MED INC: BUSINESS OVERVIEW 192
- 12.1.17 TULIP (P) DIAGNOSTICS LTD 194
- TABLE 135 TULIP (P) DIAGNOSTICS LTD: BUSINESS OVERVIEW 194
- 12.1.18 BTNX INC. 195
- TABLE 136 BTNX INC.: BUSINESS OVERVIEW 195
- 12.1.19 RESPONSE BIOMEDICAL 196
- TABLE 137 RESPONSE BIOMEDICAL: BUSINESS OVERVIEW 196
- 12.1.20 ALFA SCIENTIFIC DESIGNS, INC. 198
- TABLE 138 ALFA SCIENTIFIC DESIGNS, INC: BUSINESS OVERVIEW 198
- 12.2 OTHER PLAYERS 199
- 12.2.1 CTK BIOTECH, INC. 199
- 12.2.2 CREATIVE DIAGNOSTICS 199
- 12.2.3 LIFESIGN LLC. 200
- 12.2.4 CARDIOGENICS HOLDINGS INC 200
- 12.2.5 ATLAS MEDICAL GMBH 201
- *Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
- 13 APPENDIX 202
- 13.1 DISCUSSION GUIDE 202
- 13.2 KNOWLEDGESTORE: MARKETSandMARKETS' SUBSCRIPTION PORTAL 206
- 13.3 CUSTOMIZATION OPTIONS 208
- 13.4 RELATED REPORTS 209
- 13.5 AUTHOR DETAILS 210

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Cardiac Marker Testing Market by Product (Reagent, Instrument), Component (Troponin I & T, CK-MB, Myoglobin, BNP, hs-CRP), Disease (Myocardial Infarction, Congestive Heart Failure, Atherosclerosis), Enduser (Lab, PoC, Academia) - Global Forecast to 2027

Market Report | 2022-10-12 | 205 pages | MarketsandMarkets

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

ORDER FORM:

| Select license | License | Price |
|----------------|-------------------------|------------|
| | Single User | \$4950.00 |
| | Multi User | \$6650.00 |
| | Corporate License | \$8150.00 |
| | Enterprise Site License | \$10000.00 |
| | | VAT |
| | | Total |

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

| | | | |
|---------------|----------------------|-------------------------------|----------------------|
| Email* | <input type="text"/> | Phone* | <input type="text"/> |
| First Name* | <input type="text"/> | Last Name* | <input type="text"/> |
| Job title* | <input type="text"/> | | |
| Company Name* | <input type="text"/> | EU Vat / Tax ID / NIP number* | <input type="text"/> |
| Address* | <input type="text"/> | City* | <input type="text"/> |

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Zip Code*

Country*

Date

2026-03-17

Signature

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com